Health Catalyst, Inc. (HCAT) stock
HCATNasdaqServices-Computer Programming, Data Processing, Etc.Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3075% below fair value
$1.37−0.01 (-0.72%)
Close on Nov 17, 2026Market cap $103.10MP/E –Yield –
Health Catalyst r&d expenses
Research and development expenses are spending on new products and technology.
Health Catalyst's R&D Expenses for the twelve months ending Jun 30, 2026 was $43.00M, down 24.3% year over year. For fiscal 2025 it was $49.77M, down 14.1% from the year before. The highest annual figure on record is $75.68M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.77M | -14.1% |
| FY2024 | Dec 31, 2024 | $57.95M | -20.2% |
| FY2023 | Dec 31, 2023 | $72.63M | -4.0% |
| FY2022 | Dec 31, 2022 | $75.68M | +20.6% |
| FY2021 | Dec 31, 2021 | $62.73M | +17.2% |
| FY2020 | Dec 31, 2020 | $53.52M | +15.7% |
| FY2019 | Dec 31, 2019 | $46.25M | +19.8% |
| FY2018 | Dec 31, 2018 | $38.59M | +35.6% |
| FY2017 | Dec 31, 2017 | $28.47M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $11.03M | -11.0% |
| Q1 FY2026 | Mar 31, 2026 | $9.78M | -35.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.91M | -33.9% |
| Q3 FY2025 | Sep 30, 2025 | $12.28M | -13.5% |
| Q2 FY2025 | Jun 30, 2025 | $12.39M | -10.7% |
| Q1 FY2025 | Mar 31, 2025 | $15.19M | +2.1% |
| Q4 FY2024 | Dec 31, 2024 | $15.00M | -26.1% |
| Q3 FY2024 | Sep 30, 2024 | $14.19M | -19.7% |
| Q2 FY2024 | Jun 30, 2024 | $13.88M | -21.1% |
| Q1 FY2024 | Mar 31, 2024 | $14.87M | -12.9% |
| Q4 FY2023 | Dec 31, 2023 | $20.29M | +3.4% |
| Q3 FY2023 | Sep 30, 2023 | $17.67M | -14.9% |
| Q2 FY2023 | Jun 30, 2023 | $17.59M | -3.1% |
| Q1 FY2023 | Mar 31, 2023 | $17.08M | -0.4% |
| Q4 FY2022 | Dec 31, 2022 | $19.61M | +12.2% |
| Q3 FY2022 | Sep 30, 2022 | $20.77M | +26.8% |
| Q2 FY2022 | Jun 30, 2022 | $18.15M | +25.0% |
| Q1 FY2022 | Mar 31, 2022 | $17.15M | +19.5% |
| Q4 FY2021 | Dec 31, 2021 | $17.48M | +16.7% |
| Q3 FY2021 | Sep 30, 2021 | $16.39M | +22.4% |
| Q2 FY2021 | Jun 30, 2021 | $14.52M | +20.4% |
| Q1 FY2021 | Mar 31, 2021 | $14.35M | +9.6% |
| Q4 FY2020 | Dec 31, 2020 | $14.98M | +14.8% |
| Q3 FY2020 | Sep 30, 2020 | $13.39M | -0.6% |
| Q2 FY2020 | Jun 30, 2020 | $12.06M | +24.2% |
| Q1 FY2020 | Mar 31, 2020 | $13.09M | +30.6% |
| Q4 FY2019 | Dec 31, 2019 | $13.04M | +23.5% |
| Q3 FY2019 | Sep 30, 2019 | $13.48M | +24.3% |
| Q2 FY2019 | Jun 30, 2019 | $9.71M | +14.4% |
| Q1 FY2019 | Mar 31, 2019 | $10.02M | – |
| Q4 FY2018 | Dec 31, 2018 | $10.56M | – |
| Q3 FY2018 | Sep 30, 2018 | $10.84M | – |
| Q2 FY2018 | Jun 30, 2018 | $8.49M | – |
See a number that looks wrong?